Health · Pharma & Biotech · 1 hr ago

HLB Therapeutics' US trial of eye treatment misses main efficacy goal

HLB Therapeutics' US trial of eye treatment misses main efficacy goal

HLB Therapeutics said its RGN-259 eye-drop candidate missed the main goal in a US phase 3 trial.

The test, run by its US subsidiary RegeneTree, found no statistically significant difference in healing rates after four weeks between people given RGN-259 and those given a placebo.

The candidate is being developed to treat neurotrophic keratitis, a rare eye disease in which damaged corneal nerves reduce sensation and the eye’s ability to heal itself.

RGN-259 contains thymosin beta-4, a protein intended to promote tissue repair and nerve regeneration.

The candidate also failed to show statistical efficacy in a European phase 3 trial, according to the company.

HLB Therapeutics plans to review the full results, including secondary measures and responses in subgroups, before deciding on its development plans and any next steps.

2 sources

Related

What people are saying

HLB Therapeutics spokespersonCompany spokesperson
분석 결과를 바탕으로 향후 개발 방향과 계획을 신중하게 검토하고, 필요한 후속 조치를 신속하고 책임 있게 추진하겠다
via Yonhap